Analysis of research hotspots and trends of phytoestrogens for menopausal syndrome based on CiteSpace
10.3760/cma.j.cn115624-20241205-01002
- VernacularTitle:基于CiteSpace分析植物雌激素用于绝经综合征的热点与趋势
- Author:
Xiaonan MA
1
;
Rong CHEN
1
Author Information
1. 中国医学科学院北京协和医学院北京协和医院妇产科 国家妇产疾病临床医学研究中心，北京 100730
- Publication Type:Journal Article
- Keywords:
Menopausal syndrome;
Phytoestrogens;
CiteSpace
- From:
Chinese Journal of Health Management
2025;19(3):220-225
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the research hotspots and trends of phytoestrogens for menopausal syndrome based on CiteSpace.Methods:The research articles were retrieved with the search terms of"phytoestrogens""perimenopause""phytoestrogens"and"perimenopause". A total of 405 articles in PubMed database from 1996 to 2023 and 227 articles in CNKI full-text database from 2000 to 2023 were retrieved. The software CiteSpace 6.2.R6 was used to visualize the articles to explore the research hotspots and trends of phytoestrogens used in menopausal syndrome.Results:A total of 632 literatures were included, and the country with a large number of publications and a high degree of central intermediation was the United States (70 publications, 0.05 intermediation centrality). Although Chinese scholars had high publication output (12 articles), they lacked external exchanges and cooperation (0 intermediary centrality). Domestic and foreign research focused on the common source of phytoestrogens, hot flushes, sweating and other common menopausal symptoms, cardiovascular diseases, breast diseases. The research direction had gradually shifted from basic research to clinical research, and more and more natural phytoestrogens types had attracted attention. In contrast, domestic research focused more on bone health, focusing on the long-term benefits of menopausal hormone therapy for patients with low bone mass and osteoporosis.Conclusion:The study of phytoestrogens for menopausal syndrome is based on evidence-based medicine and is developing towards individualized and benefit-risk ratio maximization, but there is still a lack of high-quality randomized controlled studies.
